Teladoc (TDOC) Director Increases Holdings by 1,016 RSUs and Shares

Rhea-AI Filing Summary

Jason Eric Evans, a director of Teladoc Health, Inc. (TDOC), reported transactions dated 09/19/2025 on Form 4. The filing shows acquisition of 1,016 restricted stock units that convert one-for-one into common shares, and the reporting person acquired 1,016 shares of common stock on the same date. After the transactions, the reporting person beneficially owned 8,129 shares of common stock and 4,066 derivative securities representing underlying common stock. The RSUs were part of a grant originally awarded on 09/20/2023 totaling 12,195 RSUs with a stated vesting schedule. The form is signed by an attorney-in-fact on 09/22/2025.

Positive

• Director Jason Eric Evans reported an acquisition of 1,016 RSUs and 1,016 common shares on 09/19/2025, increasing his beneficial ownership.
• The filing discloses the 09/20/2023 grant of 12,195 RSUs and a clear vesting schedule, providing transparency on equity compensation.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider acquisition of RSUs and shares by a director; increases beneficial ownership but appears procedural.

The Form 4 discloses that Director Jason Eric Evans acquired 1,016 restricted stock units and 1,016 common shares on 09/19/2025, increasing total beneficial holdings to 8,129 shares and 4,066 derivative securities. The RSUs convert one-for-one and were part of a 12,195-RSU grant dated 09/20/2023 with a multi-period vesting schedule. This filing documents standard equity compensation vesting and a contemporaneous acquisition; it does not include financial results or indications of broader corporate actions.

Corporate Governance Expert

TL;DR: Director transaction reflects scheduled vesting and an ordinary securities acquisition; disclosure follows Section 16 reporting requirements.

The disclosure indicates the director received vested RSUs that convert to common stock and recorded the acquisition consistent with Rule 16 reporting. The filing references the original 09/20/2023 RSU grant of 12,195 units and clarifies the vesting cadence. The signature by an attorney-in-fact on 09/22/2025 completes the procedural filing. No departures, option exercises with cash consideration, or unusual terms are reported.

Insider Trade Summary

1,016 shares exercised/converted

Mixed 2 txns

Insider Evans Jason Eric

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,016	$0.00	--
Exercise	Common Stock	1,016	$0.00	--

Holdings After Transaction: Restricted Stock Units — 4,066 shares (Direct); Common Stock — 8,129 shares (Direct)

Footnotes (1)

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. On September 20, 2023, the reporting person was granted 12,195 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Jason Eric

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.

155 E 44TH ST, FLOOR 17

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		M		1,016	A	(1)	8,129	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/19/2025		M			1,016	(2)	(2)	Common Stock	1,016	$0	4,066	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. On September 20, 2023, the reporting person was granted 12,195 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TDOC director Jason Eric Evans report on Form 4 filed in September 2025?

The Form 4 reports acquisition of 1,016 restricted stock units and 1,016 common shares on 09/19/2025, increasing beneficial ownership to 8,129 shares and 4,066 derivative securities.

How do the restricted stock units reported by the TDOC director convert to common stock?

The filing states the restricted stock units convert to shares on a one-for-one basis.

When was the RSU grant that included these units originally awarded?

The RSUs were part of a grant awarded on 09/20/2023 totaling 12,195 restricted stock units with staged vesting.

How many total RSUs and shares does the reporting person beneficially own after the transactions?

After the reported transactions the reporting person beneficially owned 8,129 shares of common stock and 4,066 derivative securities representing underlying common stock.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Adam C. Vandervoort, Attorney-in-Fact on 09/22/2025.